sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 25, 2026

Goldman or Citigroup: Which Transformation Story Is More Compelling?

View original at finance.yahoo.com
Goldman or Citigroup: Which Transformation Story Is More Compelling? Wall Street’s largest institutions are redefining what sustainable growth looks like…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Goldman is targeting high-teens returns for the AWM division and roughly 5% annual growth in long-term fee-based net inflows over the medium term

    80% confidence
  • For investors seeking combination of earnings durability, strategic clarity and long-term upside, GS emerges as more compelling transformation story and stronger stock to own

    80% confidence
  • Asset Management unit intends to expand private credit portfolio to $300 billion by 2029

    80% confidence
  • Citigroup expects revenues to see compounded annual growth rate of 4-5% by 2026-end and will drive $2-2.5 billion of annualized run rate savings

    80% confidence
  • Management continues to target return on tangible common equity of 10-11% in 2026

    80% confidence
  • Goldman offers clearer growth narrative backed by strengthening fundamentals, upward earnings revisions and strategic focus on high-margin, scalable businesses

    80% confidence
  • Citigroup is primarily in repair mode with near-term story revolving around cost cuts, divestitures and capital redeployment rather than organic competitive expansion

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Goldman or Citigroup: Which Transformation Story Is More Compelling? — Source | Via News | pt.VIA.NEWS